Providing a VOICE for Missouri's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2003
Meetings & Education
State Society Education Series
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
MOS Corporate Members
Become a Supporter
Industry News Archive
FDA Approves Pembrolizumab for Treatment of PMBCL
On June 13, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.
Read the FDA press release here.
Tweets by MO_Oncology